Functional epigenomic liquid biopsy identifies potential therapeutic vulnerabilities after enfortumab vedotin–pembrolizumab resistance in metastatic urothelial carcinoma (mUC)
This study demonstrates that longitudinal functional epigenomic liquid biopsy using H3K4me2 cfChIP-seq can identify dynamic regulatory reprogramming and emerging therapeutic vulnerabilities, such as ERBB2 activation, in metastatic urothelial carcinoma patients developing resistance to enfortumab vedotin–pembrolizumab, thereby offering a strategy to guide subsequent biomarker-driven treatment.